Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy Evaluation of Dotarem®-Enhanced MRA Compared to Gadovist®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Limb Arterial Diseases

NCT01026389 is registered in ClinicalTrials.gov with Guerbet as lead sponsor.

NCT NCT01026389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01026389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy Evaluation of Dotarem®-Enhanced MRA Compared to Gadovist®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Limb Arterial Diseases
Lead sponsor
Guerbet
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2009
Completion date
January 31, 2012
Enrollment
189 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral arterial disease